Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance Inc. WBA, +0.97% shares rose 2.6% in Thursday premarket trading after the pharmacy retailer reported fiscal first-quarter results that beat expectations and raised its full-year guidance. Net income totaled $3.58 billion, or $4.13 per share, after a loss of $308 million, or 36 cents per share, last year.

Walgreens raises full year guidance, creates new healthcare reporting segment

Walgreens Boots Alliance Inc on Thursday posted a profit for the first quarter versus a year-ago loss, as strong demand for COVID-19 vaccinations and testing buoyed sales at its pharmacy stores.

Walgreens swings to profit as COVID-19 testing, vaccinations lift pharmacy sales

Walgreens beat analysts' expectations for fiscal first-quarter earnings, as customers came to stores for Covid vaccines and tests.

Walgreens shares rise after its earnings get lift from Covid vaccines and testing, raises forecast

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2022, which ended November 30, 2021.

Walgreens Boots Alliance Exceeds Expectations for Fiscal 2022 First Quarter Earnings and Raises Guidance for Fiscal Year

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margins significantly.

Walgreens Boots (WBA) Gains From New Pacts, Faces Margin Woes

Walgreens Boots Alliance is scheduled to report its fiscal Q1 2022 results on Thursday, January 6. We expect the company to likely post revenue and earnings slightly above the street expectations, primarily driven by post-pandemic recovery in all segments as well as continued Covid-19 vaccine.

What To Expect From Walgreens Stock As It Reports Its Q1 Results?

Amgen

Chevron

Dow Inc

Intel

Coca-Cola

Merck

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The decades-old income-and-value strategy, the Dogs of the Dow, will try to bounce back in 2022. Here are this year's 10 members.

Dogs of the Dow 2022: 10 Dividend Stocks to Watch

Bed Bath & Beyond

Constellation Brands

While the December-quarter earnings season does not get started until next week, there are several interesting reports due out this week from companies that follow calendar-agnostic fiscal years.

Earnings Previews: Bed Bath & Beyond, Constellation Brands, Walgreens and More

DEERFIELD, Ill.--(BUSINESS WIRE)--WBA announced that Roz Brewer and Global CFO, James Kehoe, will present at J.P. Morgan Healthcare Conference, Tues., Jan. 11 at 2:15 pm (Eastern).

Walgreens Boots Alliance to Participate in 40th Annual J.P. Morgan Healthcare Conference

Target

We believe that Walgreens Boots Alliance stock currently appears to be attractive compared to its peer Target stock, due to its comparatively lower valuation and better growth prospects. WBA trades at about 0.3x trailing revenues, compared to 1.1x for TGT.

Should You Buy Walgreens Stock Over This Retailer?

Cisco Systems

Here are the newest stocks to join the portfolio for those using this easy-to-follow strategy.

Meet the 2022 Dogs of the Dow

On Monday, Walgreens Boots Alliance Inc. (NASDAQ:WBA) shares surged more than 1% after receiving an offer of around $8.1 billion for Boots UK from private equity firm Bain Capital. Sky News broke the news early last month that the US-based drugstore was exploring options to sell Boots UK.

Walgreens Boots Alliance stock forecast after receiving an offer for UK subsidiary

Bain Capital reportedly approached Walgreens Boots Alliance Inc (NASDAQ: WBA) months ago about taking over Boots, although Walgreens didn't comment on the matter. The Sunday Times said Walgreens “received a takeover approach from Bain Capital more than two months ago” and is “positioning itself as a frontrunner in a forthcoming auction for Boots after completing months of due diligence.

Bain Capital Reportedly Eyeing Boots UK Takeover From Walgreens: Report

Walgreens Boots Alliance might be looking to sell its Boots pharmacies in the U.K., with private equity firms likely being the recipients, a Saturday (Jan. 1) Forbes report says. Bain Capital reportedly approached Walgreens months ago about taking over Boots, although Walgreens didn't comment on the matter.

Bain Said to Eye Takeover of Boots UK From Walgreens

Walgreens Boots Alliance Inc (NASDAQ: WBA) has reportedly received a takeover offer from Bain Capital for the Boots drugstore chain in the UK. These are the details.

Walgreens (WBA) Reportedly Receives Takeover Offer From Bain Capital For Boots

Costco

Conagra Brands, Constellation Brands, and Walgreens Boots Alliance report quarterly results. Plus, December employment data, manufacturing and services PMIs, and FOMC minutes.

Walgreens, Costco, Constellation Brands, and Other Stocks to Watch This Week

Walgreens Boots Alliance may sell its Boots pharmacies in the United Kingdom to private equity firms, according to media reports over the weekend.

Reports: Walgreens May Sell Boots U.K. Pharmacies To Private Equity

In 2019, the Dow Jones industrial average rose by 22.34%. In 2020, the COVID-19 pandemic cut that growth spurt by two-thirds, for a gain of just 7.25%.

2022's Dogs of the Dow

Apple

American Express

Boeing

Goldman Sachs

Honeywell

JPMorgan Chase & Co

Procter & Gamble

UnitedHealth Group

Visa

Walmart

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration." Thirty-one Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated net-gains ranged 14.16%-28.38% topped by BA 12/29/21.

January Dogs Of The Dow Need A Pullback

Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Walgreens Boots Alliance (WBA) Reports Next Week: What Awaits?

When U.S. markets opened for trading on August 31, 2020, there were three new stocks in the Dow Jones industrial average.

Meet the Preliminary Dogs of the Dow for 2021

Blue-chip name Walgreens Boots Alliance Inc (NASDAQ:WBA) is gearing up for its fiscal first-quarter earnings, which is due out before the open on Thursday, Jan. 6.

Walgreens Boots Alliance Prepares for Earnings

CrowdStrike

JD.com

Annaly Capital

Growth, value, and income investors can still find incredible bargains in this market.

Got $1,000? 5 Stocks to Buy to Start 2022 With a Bang

Exxon Mobil

It is hard to believe, but 2021 will end in just a little over a week. Many investors will be reviewing their portfolios and making changes for 2022.

The 5 Highest-Yielding ‘Strong Buy' Dow Stocks Are Outstanding 2022 Ideas

Walgreens Boots Alliance (WBA) closed at $48.83 in the latest trading session, marking a -0.04% move from the prior day.

News for Walgreens Stock (WBA)